Orthofix Medical Inc. (NASDAQ: OFIX) experienced a significant decline in its share price, dropping by 5.8% during trading on Tuesday. The dip followed the company’s announcement of weaker than expected quarterly earnings. Shares fell to a low of $12.39 before closing at $12.7950. Approximately 185,213 shares changed hands, marking a 17% decrease from the average daily trading volume of 223,713 shares.
The company reported a loss of ($0.06) earnings per share for the quarter, falling short of the consensus estimate of $0.44 by ($0.50). Orthofix Medical recorded revenue of $219.91 million, surpassing analyst expectations of $218.72 million. Despite the slightly better revenue figure, the overall financial performance has raised concerns among investors.
Analyst Ratings and Future Projections
Several analysts have recently commented on Orthofix Medical’s performance. Barrington Research reiterated an “outperform” rating with a price target of $18.00. TD Cowen initiated coverage with a “hold” rating, setting a price target of $14.00. Stifel Nicolaus also initiated coverage, giving Orthofix a “buy” rating and a price objective of $22.00. In contrast, Weiss Ratings maintained a “sell (d-)” rating on the stock.
Currently, four research analysts rate the stock as a Buy, two as Hold, and one as Sell. According to data from MarketBeat, the stock holds a consensus rating of “Hold” with an average target price of $20.00.
Insider Transactions and Institutional Investments
In other company news, CEO Massimo Calafiore sold 9,797 shares on January 12, 2024, at an average price of $15.21, totaling $149,012.37. Following this transaction, his remaining shares are valued at approximately $3,304,174.77. This sale represented a 4.32% reduction in his ownership stake.
CFO Julie Andrews also sold 4,873 shares on January 16, 2024, for a total value of $70,073.74. Post-sale, she holds 58,039 shares valued at around $834,600.82, reflecting a 7.75% decrease in her position. Over the past quarter, insiders have sold a total of 24,270 shares worth $370,958. Insiders now own 1.30% of the company’s stock.
Institutional investors have been active as well, with several adjusting their stakes in Orthofix Medical. CWM LLC increased its stake by 99.0% in the third quarter, now holding 1,920 shares valued at $28,000. The State of Alaska Department of Revenue also acquired a new stake worth approximately $30,000. Other notable investments include Kestra Advisory Services LLC, which purchased shares worth about $56,000, and Mackenzie Financial Corp, acquiring a stake valued at approximately $148,000. Overall, institutional investors and hedge funds own 89.76% of Orthofix Medical’s stock.
In terms of financial ratios, Orthofix Medical has a quick ratio of 1.38, a current ratio of 2.47, and a debt-to-equity ratio of 0.39. The stock’s 50-day moving average is $14.27, while the 200-day moving average is $14.72. The company has a market capitalization of $504.11 million, with a price-to-earnings ratio of -4.20 and a beta of 0.78.
Company Overview
Orthofix Medical Inc. is a global leader in the design and development of innovative orthopedic and spinal solutions. The company operates in two primary segments: spine and orthopedics. In the spine segment, Orthofix provides a range of titanium implants, biologics, and portable bone growth stimulation devices aimed at supporting spinal fusion and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, trauma care, and sports medicine, offering surgeons advanced tools for complex bone reconstruction and healing.
The company’s diverse product portfolio includes strut systems, bone growth stimulators, interbody fusion devices, and fixation hardware, addressing various medical conditions such as degenerative disc disease and long-bone fractures.
For ongoing updates and insights into Orthofix Medical, interested parties can subscribe to receive daily summaries of company news and analyst ratings through platforms like MarketBeat.
